Cargando…

New Markers for Cardiovascular Disease in Psoriatic Patients: Preliminary Study on Monocyte Phenotype, ADAMTS7, and mTOR Activity

Psoriasis is a skin disease with occasional involvement of non-cutaneous territories. Beyond the usual, cardiovascular events are more frequent in these patients and correlate only partially with disease activity, suggesting the presence of other unknown factors. We selected ten psoriatic patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loyola, Khanty, Karsulovic, Claudio, Cabrera, Raúl, Perez, Claudio, Hojman, Lía
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864195/ https://www.ncbi.nlm.nih.gov/pubmed/36677041 http://dx.doi.org/10.3390/metabo13010116

Ejemplares similares

Non-Canonical WNT/Wnt5a Pathway Activity in Circulating Monocytes of Untreated Psoriatic Patients: An Exploratory Study of Its Association with Inflammatory Cytokines and Cardiovascular Risk Marker-ADAMTS7
por: Karsulovic, Claudio, et al.
Publicado: (2023)

Cardiovascular Disease-Associated Skin Conditions
por: Hojman, Lia, et al.
Publicado: (2022)

Diffuse Lymphadenopathy Syndrome as a Flare-Up Manifestation in Lupus and Mixed Connective Tissue Disease Following Mild COVID-19
por: Karsulovic, Claudio, et al.
Publicado: (2021)

In vitro Phenotype Induction of Circulating Monocytes: CD16 and CD163 Analysis
por: Karsulovic, Claudio, et al.
Publicado: (2021)

mTOR inhibition impairs extinction memory reconsolidation
por: Radiske, Andressa, et al.
Publicado: (2021)

mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target
por: Raychaudhuri, Smriti K, et al.
Publicado: (2014)

Exploring mTOR inhibition as treatment for mitochondrial disease
por: Sage‐Schwaede, Abigail, et al.
Publicado: (2019)

Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines
por: Lin, Hugo You-Hsien, et al.
Publicado: (2014)

mTORC inhibitor Sirolimus deprograms monocytes in “cytokine storm” in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome
por: Karsulovic, Claudio, et al.
Publicado: (2020)

Morphology, clearing efficacy, and mTOR dependency of the organelle autophagoproteasome
por: Limanaqi, Fiona, et al.
Publicado: (2021)

mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership
por: Cayo, Angel, et al.
Publicado: (2021)

Endothelial mTOR maintains hematopoiesis during aging
por: Ramalingam, Pradeep, et al.
Publicado: (2020)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Inhibition of Mast Cell Function and Proliferation by mTOR Activator MHY1485
por: Rakhmanova, Valeriya, et al.
Publicado: (2018)

Follicular vitiligo: dermatoscopic features of a new subtype of vitiligo
por: Cabrera, Raúl, et al.
Publicado: (2019)

Cardiac natriuretic peptides promote adipose ‘browning’ through mTOR complex-1
por: Liu, Dianxin, et al.
Publicado: (2018)

mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors
por: Wu, Tingting, et al.
Publicado: (2016)

mTOR regulation of metabolism limits LPS-induced monocyte inflammatory and procoagulant responses
por: Lund, Nina C., et al.
Publicado: (2022)

Reversal of phenotypes of cellular senescence by pan-mTOR inhibition
por: Walters, Hannah E., et al.
Publicado: (2016)

Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2020)

ADAMTS13 Gene Mutations in Children with Hemolytic Uremic Syndrome
por: Choi, Hyoung Soo, et al.
Publicado: (2011)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Treponema pallidum Dysregulates Monocytes and Promotes the Expression of IL-1β and Migration in Monocytes Through the mTOR Signaling Pathway
por: Liu, Wen-Na, et al.
Publicado: (2020)

Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study
por: Scriffignano, Silvia, et al.
Publicado: (2022)

ADAMTS-4 activity in synovial fluid as a biomarker of inflammation and effusion
por: Roberts, S., et al.
Publicado: (2015)

ADAMTS13 regulation of VWF multimer distribution in severe COVID‐19
por: Ward, Soracha E., et al.
Publicado: (2021)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Psoriatic skin inflammation induces a pre-diabetic phenotype via the endocrine actions of skin secretome
por: Evans, Elizabeth A., et al.
Publicado: (2020)

mTOR as a Marker of Exercise and Fatigue in Octopus vulgaris Arm
por: Maiole, Federica, et al.
Publicado: (2019)

p53-mediated AKT and mTOR inhibition requires RFX7 and DDIT4 and depends on nutrient abundance
por: Coronel, Luis, et al.
Publicado: (2021)

A Moderate Decrease in ADAMTS13 Activity Correlates with the Severity of STEC-HUS
por: Emirova, Khadizha M., et al.
Publicado: (2023)

The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients – preliminary report
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2018)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ufabu94lhsl706ndpvmbule18n